Danish agency advises against use of Saxenda
The Danish Institute for Rational Pharmacotherapy is not impressed with Novo Nordisk’s Saxenda, saying there is currently no place for the product in the treatment of obesity in Denmark.
BY STEFAN SINGH KAILAY
Efficacy is inadequate, the price is too high, and the side effects are too many. That is the harsh verdict from the Danish guidance agency Institute for Rational Pharmacotherapy (IRF) over Novo Nordisk’s drug Saxenda to treat severe obesity.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo launches obesity drug in the US
For abonnenter
Novo wins approval of obesity drug in Europe
For abonnenter
